Executive Summary

Valued at 1.5 USD Billion in 2025, the Remote Patient Monitoring Devices Market is forecast to reach 6.5 USD Billion by 2035, expanding at a CAGR of 15.7%.

Two mechanisms drive the market: NICE’s TA943 extends reimbursed coverage for hybrid closed loop systems to under-18 patients and adults with HbA1c above 58 mmol/mol, and the EU MDR has formalized certification for connected cardiac monitors.

North America held 42.0% of the market in 2025, followed by Asia Pacific at 27.0% and Europe at 19.0%. Vital Sign Monitors led the product segment, the baseline category providers deploy first.

EU MDR recertification cost weighs heaviest on smaller device makers holding legacy monitors. Competition stays fragmented, with vendors differentiating on connected-platform breadth rather than scale.

Key Takeaways

• From USD 1.50 Billion in 2025, the market reaches USD 6.50 Billion by 2035 at 15.7% a year, with growth tied in part to CMS reimbursement policy for connected monitoring under existing CPT and HCPCS codes.
• Vital Sign Monitors lead on product type; most reach market through FDA 510(k) or De Novo clearance rather than the more demanding PMA route, consistent with their classification as moderate-risk devices.
• Cardiovascular Diseases holds the largest position on application, where NICE and comparable HTA bodies are conditioning coverage on demonstrated monitoring accuracy rather than device novelty alone.
• North America is the largest region at 42.0% in 2025, underpinned by CMS coverage decisions and HIPAA data-handling obligations that shape how connected monitors are deployed in US care settings.
• The report profiles 10 suppliers across a fragmented field, each carrying EU MDR conformity-assessment burden alongside 21 CFR Part 11 validation requirements for the AI software layer.

Market Definition and Scope

The Remote Patient Monitoring Devices Market covers connected vital sign, blood pressure, cardiac, respiratory and glucose monitoring devices, plus wearable trackers, that transmit patient data to clinicians outside a hospital setting. Most hardware in scope reaches the US market through the FDA’s 510(k) or De Novo pathway rather than the higher-evidence Premarket Approval (PMA) route, and companion diagnostic software sold alongside the hardware falls under EU MDR or IVDR classification in the European Union. The scope spans hardware, companion mobile applications and cloud analytics platforms used in cardiovascular disease, diabetes, respiratory disease, cancer and other chronic-condition management across hospitals, ambulatory clinics and homecare, with device and software use billed in the United States under CMS’s remote physiologic monitoring CPT and HCPCS codes. Data captured and transmitted through these platforms sits under HIPAA in the United States and GDPR wherever a patient record crosses into the European Union.

It excludes in-hospital bedside monitors that do not transmit data remotely and standalone telehealth video-consultation platforms, which sit in adjacent hospital-equipment and digital-health categories.

Growth Drivers and Restraints

NICE and EU MDR are converting diabetes and cardiac monitoring into reimbursed categories

NICE Technology Appraisal TA943 recommends hybrid closed loop systems for every patient under 18 with type 1 diabetes and for adults with HbA1c at or above 58 mmol/mol (7.5%) or disabling hypoglycaemia, pulling continuous glucose monitors from the Other Connected Monitoring Devices segment into a reimbursed pathway in England and Wales. The EU Medical Device Regulation sets parallel safety and effectiveness requirements for connected cardiac and vital sign monitors, a certification effect cited as supporting device uptake in Germany specifically. Together the two turn coverage decisions into predictable unit demand for cardiac and diabetes-linked device lines.

AI-enabled monitoring software is clearing US and UK regulatory pathways

The FDA’s January 2025 draft guidance on AI-enabled device software functions sets submission requirements covering model transparency, bias testing and change-control plans for 510(k), De Novo and PMA filings, a bar every AI-assisted cardiac and respiratory monitor now has to clear. In parallel, the MHRA’s AI Airlock sandbox moved seven candidates, including Numan’s conversational monitoring system, through its second phase running April 2025 to March 2026, giving software-driven monitoring platforms a route to market ahead of a settled regulatory framework. Vendors building analytics into vital sign and cardiac devices are the direct beneficiaries.

Legal recognition of remotely transmitted clinical data is spreading beyond North America and Europe

Brazil’s Federal Council of Medicine published Resolution CFM No. 2.264/2019 in November 2019, establishing a legal basis for clinical reporting built on remotely transmitted patient data. Germany’s device market grew specifically under the EU MDR’s certification regime. Read together, the two show that once a jurisdiction defines the legal and regulatory status of remote data, device makers gain a distinct national entry point rather than depending on the two largest markets alone, widening the base for cardiac and respiratory monitoring device sales.

EU MDR recertification cost falls hardest on legacy device lines

Recertifying an existing connected monitor under the EU MDR’s tightened safety and effectiveness requirements costs more than the original CE marking did, and makers of blood pressure and respiratory monitors carry that cost without the volume that larger cardiac-monitoring vendors have. Some legacy product lines are withdrawn from the European market rather than resubmitted. That narrows the device choices distributors can offer and concentrates share among vendors with the compliance budget to requalify.

Narrow reimbursement eligibility limits how many diabetes patients convert

NICE’s TA943 restricts hybrid closed loop coverage to patients under 18 or to adults meeting a defined HbA1c or hypoglycaemia threshold. A large share of type 1 patients outside that threshold, and most type 2 diabetics, remain outside the reimbursed pathway even where the device and connectivity already exist. Vendors selling into that gap depend on private pay or employer plans, which slows how quickly a favorable coverage decision converts into installed device volume.

Market Trends

AI-assisted monitoring analytics are moving from pilot to cleared product

Regulators are no longer treating AI-enabled monitoring software as experimental. The MHRA’s AI Airlock carried Numan’s conversational monitoring system through a second sandbox phase running April 2025 to March 2026, while the FDA’s January 2025 draft guidance set out the transparency and change-control expectations AI-enabled submissions must now meet. Cardiac and respiratory monitors that pair a sensor with an analytics layer are the segment most affected, since triage and alerting are where AI adds clinical value beyond raw readings. Expect submission volume for AI-linked monitors to keep climbing through the forecast period as both frameworks mature.

Chronic-disease management is pulling monitoring out of the clinic

Cardiovascular disease, diabetes and respiratory disease management are shifting toward continuous, connected tracking rather than periodic in-office checks, with cloud platforms aggregating readings from multiple device types into one clinician view. Patients managing hypertension, arrhythmia or COPD are the group most affected, since these conditions require frequent readings rather than one-off measurement. Demand for vital sign and cardiac monitoring devices built for daily home use is expected to grow fastest under this shift through 2035.

Continuous glucose monitors are becoming inputs to closed-loop systems, not standalone trackers

NICE’s TA943 recommends hybrid closed loop systems, which pair a continuous glucose monitor with an insulin pump and dosing algorithm, for all patients under 18 with type 1 diabetes and for adults meeting a defined HbA1c or hypoglycaemia threshold. That coverage decision is pushing glucose monitors within the Other Connected Monitoring Devices segment away from standalone display-and-alert designs and toward sensors built to feed an automated dosing system, a shift diabetes device makers are following into their own product roadmaps.

Segment Analysis

By Product Type

• Vital Sign Monitors (largest) – Devices that track core physiological parameters such as temperature, pulse, and oxygen saturation and relay readings to clinicians outside a hospital setting

• Pulse Oximeters
• Temperature Monitors
• Multi-Parameter Vital Sign Monitors
• Weighing Scales
• Blood Pressure Monitors – Wearable or cuff-based devices that measure systolic and diastolic arterial pressure and transmit readings to a care provider for remote review

• Upper Arm Monitors
• Wrist Monitors
• Cuffless Monitors
• Cardiac Monitoring Devices – Wearable sensors, patches, or implants that track heart rhythm and electrical activity to flag arrhythmias and other cardiac events for remote clinical review

• ECG/EKG Monitors
• Holter Monitors
• Event Monitors
• Implantable Cardiac Monitors
• Mobile Cardiac Telemetry Devices
• Respiratory Monitoring Devices – Devices that measure breathing rate, airflow, or blood oxygen saturation to track pulmonary conditions such as COPD, asthma, or sleep apnea from home

• Spirometers
• Sleep Apnea Monitors

• Polysomnography (PSG) Devices
• Home Sleep Apnea Test (HSAT) Devices

• Capnography Monitors
• Peak Flow Meters
• Other Connected Monitoring Devices – A grouping of remaining connected tools, including glucose sensors, smart weight scales, and pulse oximeters, that feed patient data into remote monitoring platforms

• Blood Glucose Monitors
• Fetal and Neonatal Monitors
• Neuromonitoring Devices
• Wearable Activity/Health Trackers

Vital Sign Monitors lead product-type demand with a 48.6% share in 2025. Most units in this category clear the US FDA as Class II devices under the 510(k) pathway rather than the more demanding PMA or De Novo routes, which keeps time-to-market short and supports the category’s role as the default first purchase for hospital-at-home and post-discharge programs; the same pulse oximeters, temperature monitors, multi-parameter units and connected scales form the baseline data set that every remote monitoring program deploys before layering on disease-specific devices. Reimbursement follows the hardware. CMS pays for remote physiologic monitoring under dedicated CPT/HCPCS codes, and vendors handling that data in the United States must meet HIPAA safeguards and, where software components generate or store the electronic records, 21 CFR Part 11 controls. Cardiac Monitoring Devices are expanding fastest within the axis. Wearable ECG patches, mobile cardiac telemetry and implantable loop recorders are substituting for episodic in-clinic Holter studies as arrhythmia detection shifts toward continuous, ambulatory capture, and in the European Union that shift has run alongside EU MDR recertification of legacy cardiac monitors, pushing some smaller device lines through the compliance backlog that MDR created for existing 510(k)-cleared analogues sold outside the US.

By Application

• Cardiovascular Diseases (largest) – Wearable and implantable sensors that track heart rate, rhythm, blood pressure, or fluid status in patients managing conditions such as hypertension, arrhythmia, or heart failure outside the clinic

• Hypertension
• Cardiac Arrhythmia
• Heart Failure
• Coronary Artery Disease

• Diabetes – Continuous glucose monitors and connected blood glucose meters that transmit blood sugar readings to patients and care teams to guide insulin dosing and lifestyle adjustments
• Respiratory Diseases – Connected pulse oximeters, spirometers, and peak flow meters used to track oxygen saturation and lung function in patients with conditions like COPD or asthma

• Chronic Obstructive Pulmonary Disease (COPD)
• Asthma
• Sleep Apnea

• Cancer – Monitoring tools that track vital signs, symptoms, and treatment side effects in oncology patients undergoing chemotherapy or post-surgical recovery at home
• Other Chronic Conditions – Devices tracking indicators such as weight, activity, or neurological signs for conditions like obesity, kidney disease, or musculoskeletal disorders not covered by the other categories

• Neurological Disorders
• Obesity/Weight Management
• Renal Disease

Cardiovascular Diseases is the leading application. The CDC counts hypertension, arrhythmia and heart failure among the largest drivers of chronic-disease burden in the United States, and hospital systems have built discharge and chronic-care programs around blood-pressure and cardiac-rhythm data because the cost of a missed deterioration event is high and readily measurable against readmission penalties; in Europe, national HTA bodies including NICE now factor remote cardiac monitoring into coverage reviews once a device carries EU MDR certification. Diabetes is growing fastest among applications. Continuous glucose sensors and connected meters are displacing periodic fingerstick testing as patients and endocrinology teams push for real-time glycemic data, and manufacturers seeking access to the Indian market route new sensor models through CDSCO registration rather than relying on a US 510(k) clearance alone. Sponsors validating these sensors in multi-country trials follow ICH GCP protocols, and standalone CGM sensors clear the EU market through MDR notified-body conformity assessment rather than the EMA centralised procedure, which stays reserved for the drug side of any combination insulin-dosing product; either way, patient glucose data collected in the EU falls under GDPR, on top of the same cloud infrastructure built for cardiac telemetry that is now being extended to feed glucose trends into the dashboards clinicians already use.

Regional Analysis

North America

North America held 42.0% of the market in 2025, worth USD 0.63 Billion.

Asia Pacific

At 27.0% in 2025, this is the second-largest regional market, worth USD 0.41 Billion.

Europe

Europe held 19.0% of the market in 2025, worth USD 0.28 Billion.

Country Growth Comparison

United States, Germany and India illustrate three distinct paths to remote-monitoring adoption, shaped more by reimbursement design than by device availability. The United States pairs coverage for remote physiologic monitoring services with a dense hospital-at-home and home-health provider base, sustaining device pull-through once a patient leaves the acute setting. Germany’s statutory health-insurance system routes uptake through centralized technology assessment, favoring vendors able to document clinical evidence ahead of national reimbursement. India combines a large hypertension and diabetes population with an expanding domestic device-manufacturing base, making volume rather than price the primary lever for adoption.

Competitive Landscape

The remote patient monitoring devices market is fragmented, with device manufacturers, connected-health platform vendors and diagnostics companies competing across product categories rather than concentrated under a small dominant group. Competition centers on regulatory clearance status, reimbursement coding for remote monitoring services, and the installed base of connected devices that ties a health system to a vendor’s data platform and consumable sensors; clinical evidence behind continuous-monitoring endpoints and integration with hospital electronic health record and telehealth systems further separate established players from new entrants. The market is led by a group of established medical-device and diagnostics companies, including Koninklijke Philips N.V., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Smiths Medical, Nihon Kohden Corporation, Omron Corporation, F. Hoffmann-La Roche Ltd, American TeleCare, Inc., Johnson & Johnson, OSI Systems, Inc., and GE HealthCare Technologies Inc. These companies span vital-sign hardware, cardiac and respiratory device lines, and glucose and diagnostics platforms, giving each a different anchor point for expansion into adjacent remote-monitoring categories.

Strategic Outlook

The clearest whitespace lies in cardiac and respiratory monitoring for chronic-disease populations managed at home rather than post-acute alone, benefiting vendors that pair connected sensors with cloud analytics platforms already used by hospital discharge programs. Realizing it depends on reimbursement coding for remote monitoring services extending beyond the United States into other national health systems. By 2035, the product mix is expected to tilt away from single-parameter vital-sign hardware toward multi-parameter, cardiac-oriented platforms, with buyers prioritizing data interoperability and analytics over standalone device specifications.

Remote Patient Monitoring Devices Market Report Scope